AAAAAA

   
Results: 1-25 | 26-50 | 51-75 | 76-100 | >>

Table of contents of journal: *Formulary (Cleveland, Ohio)

Results: 1-25/696
PLAN SPONSORS RX DRUG COSTS ROSE 16-PERCENT LAST YEAR
Citation: PLAN SPONSORS RX DRUG COSTS ROSE 16-PERCENT LAST YEAR, Formulary (Cleveland, Ohio), 33(9), 1998, pp. 836-836
CLINDAMYCIN RESTRICTION SLASHES VA HOSPITALS CLOSTRIDIUM-DIFFICILE RESISTANCE RATES, OVERALL TREATMENT COSTS
Citation: CLINDAMYCIN RESTRICTION SLASHES VA HOSPITALS CLOSTRIDIUM-DIFFICILE RESISTANCE RATES, OVERALL TREATMENT COSTS, Formulary (Cleveland, Ohio), 33(9), 1998, pp. 836
FOCUS ON QUINUPRISTIN DALFOPRISTIN - AN INVESTIGATIONAL STREPTOGRAMINANTIBIOTIC FOR THE TREATMENT OF MULTIDRUG-RESISTANT GRAM-POSITIVE INFECTIONS/
Authors: CUPOABBOTT J HOLTOM P RHO JP
Citation: J. Cupoabbott et al., FOCUS ON QUINUPRISTIN DALFOPRISTIN - AN INVESTIGATIONAL STREPTOGRAMINANTIBIOTIC FOR THE TREATMENT OF MULTIDRUG-RESISTANT GRAM-POSITIVE INFECTIONS/, Formulary (Cleveland, Ohio), 33(9), 1998, pp. 841
DIABETES-MELLITUS THERAPY - EVALUATING THE ROLE OF THE NEWER ANTIDIABETIC AGENTS
Authors: BECKEY NP
Citation: Np. Beckey, DIABETES-MELLITUS THERAPY - EVALUATING THE ROLE OF THE NEWER ANTIDIABETIC AGENTS, Formulary (Cleveland, Ohio), 33(9), 1998, pp. 858
VANCOMYCIN UTILIZATION GUIDELINES AND RESTRICTION POLICIES - A REVIEW
Authors: BARRENTINE TF WOOD AH KENDRACH M
Citation: Tf. Barrentine et al., VANCOMYCIN UTILIZATION GUIDELINES AND RESTRICTION POLICIES - A REVIEW, Formulary (Cleveland, Ohio), 33(9), 1998, pp. 882
MEASURING HEALTH-RELATED QUALITY-OF-LIFE - AN INTRODUCTION TO SURVEY INSTRUMENTS
Authors: JOHNSON N
Citation: N. Johnson, MEASURING HEALTH-RELATED QUALITY-OF-LIFE - AN INTRODUCTION TO SURVEY INSTRUMENTS, Formulary (Cleveland, Ohio), 33(9), 1998, pp. 897
COST SAVINGS FROM A MIDAZOLAM TO LORAZEPAM THERAPEUTIC INTERCHANGE PROGRAM
Citation: COST SAVINGS FROM A MIDAZOLAM TO LORAZEPAM THERAPEUTIC INTERCHANGE PROGRAM, Formulary (Cleveland, Ohio), 33(9), 1998, pp. 905-905
ALBUMIN HETASTARCH GUIDELINE TARGETS APPROPRIATE USE, RESULTS IN REDUCED PRODUCT EXPENDITURES/
Citation: ALBUMIN HETASTARCH GUIDELINE TARGETS APPROPRIATE USE, RESULTS IN REDUCED PRODUCT EXPENDITURES/, Formulary (Cleveland, Ohio), 33(9), 1998, pp. 905-906
DRUG SAFETY SURFACES AS A LEADING ISSUE IN POLICY-MAKING, COVERAGE DECISIONS
Authors: WECHSLER J
Citation: J. Wechsler, DRUG SAFETY SURFACES AS A LEADING ISSUE IN POLICY-MAKING, COVERAGE DECISIONS, Formulary (Cleveland, Ohio), 33(9), 1998, pp. 910
GLUCAGEN - RECOMBINANT GLUCAGON FOR SEVERE HTN AND AS A RADIOLOGIC DIAGNOSTIC-AID
Citation: GLUCAGEN - RECOMBINANT GLUCAGON FOR SEVERE HTN AND AS A RADIOLOGIC DIAGNOSTIC-AID, Formulary (Cleveland, Ohio), 33(8), 1998, pp. 710
ATACAND - ANGIOTENSIN-II RECEPTOR BLOCKER FOR THE TREATMENT OF HYPERTENSION
Citation: ATACAND - ANGIOTENSIN-II RECEPTOR BLOCKER FOR THE TREATMENT OF HYPERTENSION, Formulary (Cleveland, Ohio), 33(8), 1998, pp. 710-710
SYNAGIS - MONOCLONAL-ANTIBODY TO PREVENT RESPIRATORY SYNCYTIAL VIRUS-INFECTION
Citation: SYNAGIS - MONOCLONAL-ANTIBODY TO PREVENT RESPIRATORY SYNCYTIAL VIRUS-INFECTION, Formulary (Cleveland, Ohio), 33(8), 1998, pp. 712-713
FAMVIR - ANTIVIRAL FOR RECURRENT HERPES-SIMPLEX INFECTIONS IN HIV-INFECTED PATIENTS
Citation: FAMVIR - ANTIVIRAL FOR RECURRENT HERPES-SIMPLEX INFECTIONS IN HIV-INFECTED PATIENTS, Formulary (Cleveland, Ohio), 33(8), 1998, pp. 713-713
PROLEUKIN - METASTATIC MELANOMA ADDED TO LABELING FOR INTERLEUKIN-2 AGENT
Citation: PROLEUKIN - METASTATIC MELANOMA ADDED TO LABELING FOR INTERLEUKIN-2 AGENT, Formulary (Cleveland, Ohio), 33(8), 1998, pp. 713-713
TAXOTERE - INDICATION EXPANDED TO METASTATIC BREAST-CANCER RESISTANT TO ANY CHEMOTHERAPY
Citation: TAXOTERE - INDICATION EXPANDED TO METASTATIC BREAST-CANCER RESISTANT TO ANY CHEMOTHERAPY, Formulary (Cleveland, Ohio), 33(8), 1998, pp. 713-713
ZYRTEC - FOR ALLERGIC RHINITIS, CHRONIC URTICARIA IN PATIENTS 2 TO 6 YEARS OF AGE
Citation: ZYRTEC - FOR ALLERGIC RHINITIS, CHRONIC URTICARIA IN PATIENTS 2 TO 6 YEARS OF AGE, Formulary (Cleveland, Ohio), 33(8), 1998, pp. 713
PROMETRIUM - MICRONIZED PROGESTERONE FOR SECONDARY AMENORRHEA
Citation: PROMETRIUM - MICRONIZED PROGESTERONE FOR SECONDARY AMENORRHEA, Formulary (Cleveland, Ohio), 33(8), 1998, pp. 716-716
DEPRESSION-RELATED UTILIZATION COSTS SIMILAR AMONG SSRIS
Citation: DEPRESSION-RELATED UTILIZATION COSTS SIMILAR AMONG SSRIS, Formulary (Cleveland, Ohio), 33(8), 1998, pp. 721-722
ANTIDIABETIC PROMISES POTENT GLUCOSE REDUCTION WITHOUT EVIDENCE OF TROGLITAZONES LIVER TOXICITY
Citation: ANTIDIABETIC PROMISES POTENT GLUCOSE REDUCTION WITHOUT EVIDENCE OF TROGLITAZONES LIVER TOXICITY, Formulary (Cleveland, Ohio), 33(8), 1998, pp. 721-721
SENIOR-SPECIFIC DUR REDUCES INAPPROPRIATE PRESCRIBING
Citation: SENIOR-SPECIFIC DUR REDUCES INAPPROPRIATE PRESCRIBING, Formulary (Cleveland, Ohio), 33(8), 1998, pp. 722-722
FOCUS ON CITALOPRAM - A SELECTIVE SEROTONIN REUPTAKE INHIBITOR FOR THE TREATMENT OF DEPRESSION
Authors: SCATES AC DORAISWAMY PM
Citation: Ac. Scates et Pm. Doraiswamy, FOCUS ON CITALOPRAM - A SELECTIVE SEROTONIN REUPTAKE INHIBITOR FOR THE TREATMENT OF DEPRESSION, Formulary (Cleveland, Ohio), 33(8), 1998, pp. 725
FOCUS ON RALOXIFENE - A SELECTIVE ESTROGEN-RECEPTOR MODULATOR FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN (VOL 33, PG 305, 1998)
Authors: ASHWORTH LE
Citation: Le. Ashworth, FOCUS ON RALOXIFENE - A SELECTIVE ESTROGEN-RECEPTOR MODULATOR FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN (VOL 33, PG 305, 1998), Formulary (Cleveland, Ohio), 33(8), 1998, pp. 743-743
THE ROLE OF ANTIESTROGENS IN THE TREATMENT AND PREVENTION OF BREAST-CANCER
Authors: REDDY P DEFUSCO P
Citation: P. Reddy et P. Defusco, THE ROLE OF ANTIESTROGENS IN THE TREATMENT AND PREVENTION OF BREAST-CANCER, Formulary (Cleveland, Ohio), 33(8), 1998, pp. 744
A SYSTEMS-APPROACH TO THE EVALUATION OF A DISEASE MANAGEMENT PROGRAM
Authors: MACKINNON NJ
Citation: Nj. Mackinnon, A SYSTEMS-APPROACH TO THE EVALUATION OF A DISEASE MANAGEMENT PROGRAM, Formulary (Cleveland, Ohio), 33(8), 1998, pp. 769
HOW TO EVALUATE THE COST-EFFECTIVENESS OF A VACCINE
Authors: BASSKIN L
Citation: L. Basskin, HOW TO EVALUATE THE COST-EFFECTIVENESS OF A VACCINE, Formulary (Cleveland, Ohio), 33(8), 1998, pp. 789
Risultati: 1-25 | 26-50 | 51-75 | 76-100 | >>